What are the contraindications to be aware of when taking adalimumab?

Adalimumab (Adalimumab) is a biologic agent widely used for immune system-related diseases. It mainly exerts its therapeutic effect by targeting tumor necrosis factor-α (TNF-α). It is widely used to treat rheumatoid arthritis (RA), Crohn's disease, psoriasis and many other autoimmune diseases. Although adalimumab has significant efficacy in the treatment of these diseases, there are some contraindications that need to be noted when using it to ensure patient safety.

First, use of this drug should be contraindicated in patients with known hypersensitivity to adalimumab or its components. Anaphylaxis may present with symptoms such as rash, difficulty breathing, swelling of the face or throat, and in severe cases may even cause anaphylactic shock. Patients with a history of allergies should consult their doctor before using adalimumab to assess the risks of using the drug.

Secondly, adalimumab is not suitable for patients with active tuberculosis infection. TNF-α inhibitor drugs may cause the recurrence of latent tuberculosis infection in the body. Therefore, doctors usually require patients to undergo tuberculosis screening before starting to use adalimumab. Adalimumab should be avoided in patients with any history of tuberculosis infection, especially those with active tuberculosis, unless the tuberculosis has been effectively treated.

Adalimumab should also be used with caution in patients with a history of severe heart disease. Because ofTNF-α's role in the pathogenesis of heart disease, adalimumab may worsen cardiac problems such as heart failure. For patients with a history of heart failure or heart disease, strict monitoring is required when using adalimumab.

Adalimumab should also be used with caution in patients with immune system abnormalities. Due to its ability to suppress the immune system, adalimumab may increase the risk of infections, especially bacterial, fungal, and viral infections. Patients taking adalimumab long-term are more likely to develop serious infections, including pneumonia, sepsis, and tuberculosis, and therefore need to be closely monitored for symptoms of infection during treatment.

Reference materials:https://www.drugs.com/adalimumab.html